Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Treatment of neurological injury with thymosin β4.
Relationship between NMO-antibody and anti-MOG antibody in optic neuritis.
Immunosuppressive properties of mesenchymal stem cells: advances and applications.
Less Frequent and Less Severe Flu-Like Syndrome in Interferon Beta-1a Treated Multiple Sclerosis Patients with at Least One Allele Bearing the G>C Polymorphism at Position -174 of the IL-6 Promoter Gene.
Klotho Is a Neuroprotective and Cognition-Enhancing Protein.
Breastfeeding and multiple sclerosis.
Natalizumab-associated reversible encephalopathy syndrome mimicking progressive multifocal leukoencephalopathy.
Paraoxonase 1 activity in multiple sclerosis patients during mitoxantrone therapy.
Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis.
Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab.
NICE recommends new treatment option for multiple sclerosis (Dimethyl fumarate)
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months.
Final results from the Betaseron (interferon β-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events.
Intas launches biosimilar version of Rituximab
Pharmacodynamics of Dimethyl Fumarate are Tissue-specific and Involve NRF2-dependent and -independent Mechanisms.
Biogen Idec submits application to FDA for approval of PLEGRIDY™ (peginterferon beta-1a) in multiple sclerosis
Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid.
Evaluation of pattern-reversal visual evoked potential in patients with neuromyelitis optica.
Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.
Top ten research priorities for spinal cord injury: the methodology and results of a British priority setting partnership.
MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines.
Acute transverse myelitis: demyelinating, inflammatory, and infectious myelopathies.
Disease-modifying drugs reduce cortical lesion accumulation and atrophy progression in relapsing-remitting multiple sclerosis: results from a 48-month extension study.
Interferon in relapsing-remitting multiple sclerosis.
45th European Brain and Behaviour Society Meeting

Pages